CONCLUSIONS: Our findings reveal novel insights into HSP27’s role in PC progression and its modulation of the mTOR signaling pathway in CRPC, highlighting dual HSP27/mTOR inhibition as a promising therapeutic approach for advanced, treatment-resistant disease. This evidence concerns the gene MTOR and pachyonychia congenita.